Alexion Pharmaceuticals ALXN shares are trading higher on Monday.
The company announced plans to initiate Phase 3 study of ULTOMIRIS in hospitalized patients with severe COVID-19.
Alexion is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.
Alexion shares traded up 4.36% at $107.99 on Monday. The stock has a 52-week range between $137.52 and $72.67.
Related Link:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
